1. Nat Commun. 2019 Oct 11;10(1):4622. doi: 10.1038/s41467-019-12525-7.

Integrated molecular characterization of chondrosarcoma reveals critical 
determinants of disease progression.

Nicolle R(1), Ayadi M(2), Gomez-Brouchet A(3), Armenoult L(2), Banneau G(2), 
Elarouci N(2), Tallegas M(4), Decouvelaere AV(5)(6), Aubert S(7), Rédini F(8), 
Marie B(9), Labit-Bouvier C(10), Reina N(11), Karanian M(5)(6), le Nail 
LR(8)(12), Anract P(13), Gouin F(14)(15), Larousserie F(16), de Reyniès A(2), de 
Pinieux G(17)(18).

Author information:
(1)Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le 
Cancer, Paris, France. remy.nicolle@ligue-cancer.net.
(2)Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le 
Cancer, Paris, France.
(3)Department of Pathology, CHU de Toulouse - Oncopole, Université de Toulouse, 
Toulouse, France.
(4)Plateforme de Génétique Moléculaire des Cancers, CHRU de Tours, Tours, 
France.
(5)Department of Biopathology, Centre Léon Bérard, Lyon, France.
(6)University of Lyon, Université Claude Bernard Lyon 1, CNRS 5286, INSERM 
U1052, Cancer Research Centre of Lyon, Lyon, France.
(7)Department of Pathology, CHU de Lille, Université de Lille, Lille, France.
(8)UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus 
calcifiés, Faculté de médecine, NANTES, France.
(9)Department of Pathology, CHU de Nancy, Nancy, France.
(10)Department of Pathology, CHU de Marseille, Aix Marseille Université, INSERM, 
MMG, Marseille, France.
(11)Department of Orthopedic Surgery, Hôpital Pierre-Paul Riquet, CHU de 
Toulouse, Toulouse, France.
(12)Department of Orthopedic Surgery, CHRU de Tours, Université de Tours, Tours, 
France.
(13)Department of Orthopedic Surgery, Hôpital Cochin, Assistance 
Publique-Hôpitaux de Paris, Université Paris Descartes, Sorbonne Paris Cité, 
Paris, France.
(14)Department of Surgery, Centre Léon Bérard, Lyon, France.
(15)Department of Orthopaedic Surgery, CHU Nantes, Nantes, France.
(16)Service de Pathologie, Hôpital Cochin, AP-HP, Université Paris Descartes, 
Paris, France.
(17)UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des 
tissus calcifiés, Faculté de médecine, NANTES, France. 
gonzague.dubouexic@univ-tours.fr.
(18)Department of Pathology, CHRU de Tours, Université de Tours, Tours, France. 
gonzague.dubouexic@univ-tours.fr.

Chondrosarcomas are primary cancers of cartilaginous tissue with highly 
contrasting prognoses. These tumors are defined by recurrent mutations in the 
IDH genes and other genetic alterations including inactivation of CDKN2A and 
COL2A1; however, these have no clinical value. Here we use multi-omics molecular 
profiles from a series of cartilage tumors and find an mRNA classification that 
identifies two subtypes of chondrosarcomas defined by a balance in tumor 
differentiation and cell cycle activation. The microRNA classification reveals 
the importance of the loss of expression of the 14q32 locus in defining the 
level of malignancy. Finally, DNA methylation is associated with IDH mutations. 
We can use the multi-omics classifications to predict outcome. We propose an 
mRNA-only classifier to reproduce the integrated multi-omics classification, and 
its application to relapsed tumor samples shows the progressive nature of the 
classification. Thus, it may be possible to use mRNA-based signatures to detect 
patients with high-risk chondrosarcomas.

DOI: 10.1038/s41467-019-12525-7
PMCID: PMC6789144
PMID: 31604924 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.